Apoptosis Insight Reveals Cancer Clue

31 July 1994

Researchers from the UK's Imperial Cancer Research Fund have revealed new aspects of programmed cell death, or apoptosis, which lend further weight to the importance of this process in the development of cancer and other diseases. The findings are published in the current issue of the European Molecular Biology Organization journal.

One line of thought on the nature of apoptosis which is currently popular suggests that every time a cell receives a signal instructing it to divide, it also receives a signal telling it to undergo programmed cell death (see diagram). This second signal is thought to be overcome by a second, independent signal to preserve the cell intact. Now, Gerard Evan and his colleagues at the ICRF have demonstrated this concept experimentally.

Their work centers on a gene known as c-myc, which is mutated in many types of tumor. It is thought that in the normal state, this gene is induced by growth factor stimulation and initiates cell division, and when growth factor levels decline the gene "switches off." Dr Evan's team has now proved that the gene will also set off the suicide program unless its function is dampened by extracellular factors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight